Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 653 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

Year : 2002  |  Volume : 13  |  Issue : 4  |  Page : 520-523
Cyclosporine-A Therapy in Steroid Dependent Nephrotic Syndrome: Experience in Amman, Jordan

Department of Pediatrics, King Hussein Medical Center, Amman, Jordan

Correspondence Address:
Issa Hazza
Department of Pediatrics, King Hussein Medical Center, P.O. Box 143924, Amman 11814
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 17660679

Rights and PermissionsRights and Permissions

The use of Cyclosporin-A (CsA) has been well described and is currently recommended for use in patients with steroid dependent nephrotic syndrome (SDNS), especially when they start having steroid side effects. Over a three-year period, a total of 10 patients diagnosed as having SNDS at the King Hussein Medical Center, Amman, Jordan were retrospectively studied. Their mean age was 9.53 4.9 years. All patients included in the study failed to maintain long-term remission following cyclophosphamide therapy and had all manifested at least one steroid side effect prior to the introduction of CsA. Kidney biopsy was performed on all patients and all had normal renal functions prior to the introduction of CsA. After inducing remission with conventional steroid therapy, CsA was given in a dose of 4-6 mg/Kg/day orally in two divided doses and adjusted to maintain a mean blood trough level between 100 and 150 ng/ml. Total duration of therapy ranged between six and 24 months with a mean of 17 7.7. Steroid therapy was stopped in all patients within two months of starting CsA. Four patients relapsed after 4-6 months of stopping steroids. However, remission was re-induced when low dose alternate day prednisolone therapy was added. Two patients relapsed four months after stopping CsA, which was given for 24 months. Our study suggests that CsA is effective in maintaining long-term remission and decreasing steroid requirements in patients with SDNS.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded478    
    Comments [Add]    

Recommend this journal